0 NASDAQ Companies - November 15, 2024FS Bancorp, Inc. Authorizes Additional Share RepurchasesMOUNTLAKE TERRACE, Wash., Nov. 15, 2024 (GLOBE NEWSWIRE) — FS Bancorp, Inc. (NASDAQ: FSBW) (“Company”), the holding company for 1st […]Read More
0 NYSE Companies - November 15, 2024IDT Corporation to Participate in Southwest IDEAS Investor ConferenceNEWARK, NJ, Nov. 15, 2024 (GLOBE NEWSWIRE) — IDT Corporation (NYSE: IDT), a global provider of fintech, cloud communications, and […]Read More
0 NASDAQ Companies - November 15, 2024H&E Rentals Reports Quarterly Cash DividendBATON ROUGE, La., Nov. 15, 2024 (GLOBE NEWSWIRE) — H&E Equipment Services, Inc. (NASDAQ: HEES) (“H&E”, the “Company”, d/b/a “H&E […]Read More
0 TSX Venture News - November 15, 2024Ranchero Announces Debt Settlement TransactionVANCOUVER, British Columbia, Nov. 15, 2024 (GLOBE NEWSWIRE) — Ranchero Gold Corp. (“Ranchero” or the “Company”) (TSX.V:RNCH) is pleased to […]Read More
0 NASDAQ Companies - November 15, 2024From One Truck to Industry Titan: Saia LTL Freight Celebrates 100 YearsJOHNS CREEK, Ga., Nov. 15, 2024 (GLOBE NEWSWIRE) — This year, Saia Inc. (NASDAQ: SAIA) proudly celebrates Saia LTL Freight’s […]Read More
0 NASDAQ Companies - November 15, 2024Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb SeroconversionEight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure. Two participants who discontinued NUC […]Read More
0 NASDAQ Companies - November 15, 2024Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the […]Read More
0 NASDAQ Companies - November 15, 2024Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit […]Read More